Hormones and Cancer

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/28

encourage image

There's no tags or description

Looks like no tags are added yet.

29 Terms

1
New cards
How can hormones contribute to cancer development and progression?
  • Hormones can stimulate receptor-mediated cell proliferation, increasing opportunities for mutations.


2
New cards
What four mechanisms link oestrogen to carcinogenesis?
  • Oestrogen receptor activation stimulates proliferation

  • ERK/PI3K growth pathways may be activated

  • reactive oestrogen metabolites can damage DNA

  • altered DNA repair may allow mutations to accumulate.


  • so basically either causes proliferation or DNA damage


3
New cards
Which hormone-related factors increase breast cancer risk, and why?
  • Early menarche (earlier getting period), late menopause, postmenopausal obesity and some HRT exposures increase lifetime oestrogen exposure.


4
New cards
How do combined and oestrogen-only HRT differ in endometrial cancer risk?
  • oestrogen-only stimulates endometrial proliferation and increases cancer risk in people with a uterus.

  • Adding progestogen protects the endometrium by opposing this stimulation.


5
New cards
Why is systemic HRT generally avoided after breast cancer?
  • Hormones may stimulate residual or recurrent hormone-sensitive breast cancer.

  • Non-hormonal alternatives are generally preferred, with specialist assessment of individual circumstances.


6
New cards
How does the combined contraceptive pill affect cancer risk?
  • Current or recent use is associated with a small increased breast cancer risk; longer use can increase cervical cancer risk.

  • It reduces ovarian and endometrial cancer risk, with protection that can persist after stopping.


7
New cards
How does oestrogen stimulate ER-positive breast cancer growth?
  • Oestrogen binds the oestrogen receptor, activating gene transcription and growth signalling that promote tumour-cell proliferation.


8
New cards
What are the two main endocrine approaches to treating ER-positive breast cancer?
  • Oestrogen receptor blockade with tamoxifen,

  • reduced oestrogen synthesis using aromatase inhibitors such as anastrozole, letrozole and exemestane.


9
New cards
What is tamoxifen and how does it work in breast cancer?
  • Tamoxifen is a selective oestrogen receptor modulator (SERM).

  • In breast tissue it antagonises the oestrogen receptor, reducing oestrogen-dependent gene expression and proliferation.


10
New cards

Name three aromatase inhibitors and their MOA?

  • Anastrozole, letrozole and exemestane.

  • They inhibit aromatase, reducing conversion of androgens into oestrogens

    • limits stimulation of ER-positive breast cancer.


11
New cards
Why are aromatase inhibitors generally preferred after menopause?
  • After menopause, peripheral aromatase activity is a major source of oestrogen.

  • Before menopause, ovarian oestrogen production persists, so aromatase inhibitors wouldn’t be able to target this oestrogen → wouldnt be effective enough


12
New cards
Compare tamoxifen and aromatase inhibitors, including major adverse effects.
  • Tamoxifen blocks oestrogen receptor signalling and can be used before or after menopause; important adverse effects include hot flushes and thromboembolism.

  • Aromatase inhibitors lower oestrogen synthesis, used after menopause, and can cause joint pain, bone loss and fractures.


13
New cards
What do ER, PR and HER2 mean in breast cancer?
  • ER is oestrogen receptor

  • PR is progesterone receptor

  • HER2 is human epidermal growth factor receptor 2


14
New cards
How does receptor status determine treatment for breast cancer?
  • ER-positive disease may respond to endocrine therapy.

  • HER2-positive disease may respond to HER2-targeted treatment such as trastuzumab.

  • Triple-negative disease lacks ER, PR and HER2, so these receptor-targeted treatments are not appropriate.


15
New cards
What is HER2 and how does it promote breast cancer growth?
  • HER2 is a cell-surface growth-signalling receptor.

  • Overexpression or amplification increases growth and survival signalling, contributing to tumour proliferation.


16
New cards
What is trastuzumab (Herceptin) and how does it work?
  • Trastuzumab is a chimeric monoclonal antibody (part human part mouse)

  • It interferes with HER2-associated signalling and recruits immune mechanisms, including antibody-dependent cell-mediated cytotoxicity.


17
New cards
What is antibody-dependent cell-mediated cytotoxicity (ADCC)?
  • An antibody binds an antigen on a cancer cell. Immune effector cells recognise the antibody-coated cell and attack or destroy it.

  • Trastuzumab can promote ADCC against HER2-positive cancer cells.


18
New cards
Why is trastuzumab not given as a conventional oral tablet, and what are its key risks?
  • It is a protein antibody that would be degraded in the digestive tract, so it is administered by injection or infusion.

  • risks - infusion reactions and cardiac toxicity.


19
New cards
What is triple-negative breast cancer and why is it harder to treat?
  • TNBC lacks ER, PR and HER2.

  • Endocrine therapies and conventional HER2-directed therapies do not target it effectively.

  • It can be aggressive and often requires chemotherapy and surgery, with other treatments where appropriate.


20
New cards
What newer treatment classes and examples are discussed for triple-negative breast cancer?
  • Pembrolizumab is a PD-1-blocking immunotherapy

  • olaparib and talazoparib are PARP inhibitors for selected BRCA-associated disease


21
New cards
What is the role of testosterone and DHT in prostate cancer growth?
  • Testosterone is converted by 5α-reductase to the more potent androgen DHT.

  • Androgens bind to the androgen receptor, promoting transcription of growth and survival genes in prostate cells.


22
New cards
What are the three main approaches to blocking androgen signalling in prostate cancer?
  • Androgen deprivation therapy (ADT) reduces testicular testosterone production

  • abiraterone inhibits androgen biosynthesis

  • enzalutamide inhibits androgen receptor signalling.


23
New cards
What is androgen deprivation therapy (ADT)?
  • Treatment that lowers androgen stimulation of prostate cancer, commonly through GnRH-based medical treatment or surgical orchidectomy.

  • It can initially suppress hormone-sensitive tumour growth.


24
New cards
What is abiraterone (Zytiga) and how does it work?
  • Abiraterone inhibits CYP17A1, reducing androgen synthesis in the testes, adrenal glands and tumour tissue.

    • This lowers androgen receptor stimulation and slows prostate cancer growth.


25
New cards
What is enzalutamide and how does it work?
  • Enzalutamide inhibits the androgen receptor.

  • It interferes with androgen-driven receptor activation, nuclear translocation and DNA-mediated transcription, reducing prostate cancer growth signalling.


26
New cards
What is the key difference between abiraterone and enzalutamide?
  • Abiraterone reduces androgen production by inhibiting CYP17A1.

  • Enzalutamide blocks androgen receptor signalling.


27
New cards

What are the main stages of prostate cancer?

  • Localised prostate cancer is confined to the prostate.

  • Metastatic hormone-sensitive disease has spread but responds to androgen suppression

  • . Castration-resistant disease progresses despite castrate testosterone levels (low levels of testosterone still allow cancer to grow)


28
New cards
What is castration-resistant prostate cancer and why does it develop?
  • Prostate cancer that progresses despite testosterone being reduced to castrate levels.

  • Tumour cells adapt through mechanisms such as increased androgen receptor signalling or local androgen production; they may still respond to further androgen-targeted drugs.


29
New cards
What are the major adverse effects of androgen deprivation, and how is prostate cancer monitored?
  • Low testosterone can cause hot flushes, reduced libido, erectile problems, fatigue, muscle loss, weight gain, bone thinning and gynaecomastia. (feminisation)

  • PSA is monitored alongside clinical assessment and other investigations.